The Daily PulseWorld
US exempts specialty medicines from India and 19 other nations from new tariffs
Reported by Abhishek Tiwari (Copy Editor) · The Hindu - International ·
Confirmed by a second source: Indian Express - World
Representative image · Wikimedia CommonsTariff Exemptions
India and 19 other countries will face a zero per cent tariff on certain specialty pharmaceutical products and their associated ingredients exported to the United States. The U.S. Commerce Department published the list of eligible nations in the Federal Register as part of wider trade measures.
Covered Products
The zero per cent tariff rate applies to drugs designated for rare medical conditions, infertility treatments, cell therapies, gene therapies, antibody-drug conjugates, and animal pharmaceuticals. According to the Indian Express, the waiver also covers nuclear medicines, plasma-derived therapies, and treatments for chemical, biological, radiological, and nuclear threats. Components and key starting materials used to make these specialized goods are also exempt.
Implementation
The waivers arrive as the U.S. prepares to impose a 100 per cent ad valorem tariff on certain patented pharmaceutical imports and related ingredients starting September 29. President Donald Trump originally issued a proclamation on April 2 to adjust these imports under Section 232 of the Trade Expansion Act to encourage domestic production. Generic pharmaceutical products and their ingredients do not fall under these Section 232 tariffs.
Qualifying Criteria
Qualifying products from the listed jurisdictions receive the zero per cent rate because they maintain a current or forthcoming trade and security framework agreement with the United States. Companies can also seek tariff relief for specialty drugs if the Commerce Department determines the product fulfills an urgent health need in the U.S.
Context
India remains one of the largest exporters of pharmaceutical products globally, sending billions of dollars worth of drugs to major markets like the United States each year. Trade policies involving pharmaceuticals often use targeted exemptions to protect domestic manufacturing while maintaining access to critical specialty treatments that lack local alternatives.
ExplainerWhy this matters
What Happened
The United States has introduced steep 100 per cent tariffs on certain patented pharmaceutical imports under Section 232 of the Trade Expansion Act, but carved out zero-tariff exemptions for 20 jurisdictions, including India. These waivers apply only to specialized medical products like rare disease treatments, cell therapies, and gene therapies rather than mainstream generic drugs.
Why It Matters
Tariffs directly alter the cost structure for international medical trade, affecting how foreign drug manufacturers compete in the American healthcare market. Because a major share of Indian drug exports consists of generic medicines which are currently excluded from these specific Section 232 levies, the immediate impact is narrowed, but trade and security agreements remain crucial for shielding specialized medical exports from steep protectionist duties.
What Happens Next
Companies exporting covered specialty products will need to navigate trade and security framework agreements or apply directly for relief by demonstrating urgent U.S. health needs. Observers will closely monitor whether additional countries secure similar exemptions or if the scope of the Section 232 tariffs expands further.
More in World
Representative image · PexelsWorld• UpdatedExplainerUnconfirmed — Reported by one source so farImportant
Essar Returns to Steel With $18 Billion Investment
Reported by Neha Sharma (Staff Writer) · The Hindu - International ·
